Therapeutic approaches for the treatment of renal disease in juvenile systemic lupus erythematosus: An international multicentre PRINTO study

Annals of the Rheumatic Diseases

Volumn 72, Issue 9, 2013, Pages 1503-1509

  Miettunen, Paivi M ^a   Pistorio, Angela ^b   Palmisani, Elena ^b   Ravelli, Angelo ^b,c   Silverman, Earl ^d   Oliveira, Sheila ^e   Alessio, Maria ^f   Cuttica, Ruben ^g   Mihaylova, Dimitrina ^h   Espada, Graciela ⁱ   Pasic, Srdjan ^j   Insalaco, Antonella ^k   Ozen, Seza ^l   Porras, Oscar ^m   Sztajnbok, Flavio ⁿ   Lazarevic, Dragana ^b   Martini, Alberto ^b,c   Ruperto, Nicolino ^b,c  

^a UNIVERSITY OF CALGARY   (Canada)

^b G GASLINI INSTITUTE   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

^e FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^f UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^g HOSPITAL GENERAL DE NIÑOS PEDRO DE ELIZALDE   (Argentina)

^h University Children's Hospital   (Bulgaria)

ⁱ Reumatologia   (Argentina)

^j UNIVERSITY OF BELGRADE   (Serbia)

^k BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^l HACETTEPE UNIVERSITY   (Turkey)

^m HOSPITAL NACIONAL DE NIÑOS   (Costa Rica)

ⁿ Hospital Universitario Pedro Erneasto   (Brazil)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; HYDROXYCHLOROQUINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADOLESCENT; ARTICLE; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE EXACERBATION; DRUG USE; FEMALE; GEOGRAPHY; HUMAN; JUVENILE SYSTEMIC LUPUS ERYTHEMATOSUS; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ONSET AGE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; SCHOOL CHILD; SOUTH AMERICA; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME; TREATMENT RESPONSE;

DISEASE ACTIVITY; LUPUS NEPHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT;

ADOLESCENT; AGE OF ONSET; AZATHIOPRINE; COHORT STUDIES; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HEALTH STATUS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERNATIONAL COOPERATION; LUPUS NEPHRITIS; MALE; PROSPECTIVE STUDIES; PROTEINURIA; RECURRENCE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84881479557     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-201937     Document Type: Article

References (42)

1. Austin HA, Klippel JH, Balow JE, et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986;314:614-19. (Pubitemid 16132725)
2. Boumpas DT, Austin HA III, Vaughn EM, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992;340:741-5.
3. Gourley MF, Austin HA III, Scott D, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. Ann Intern Med 1996;125:549-57. (Pubitemid 126450087)
4. Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005;353:2219-28. (Pubitemid 41697285)
5. Mina R, Brunner HI. Pediatric lupus-are there differences in presentation, genetics, response to therapy, and damage accrual compared with adult lupus? Rheum Dis Clin North Am 2010;36:53-80.
6. Hagelberg S, Lee Y, Bargman J, et al. Longterm followup of childhood lupus nephritis. J Rheumatol 2002;29:2635-42. (Pubitemid 35416975)
7. Ruperto N, Martini A, for the Paediatric Rheumatology International Trials Organisation (PRINTO). Networking in pediatrics: the example of the Pediatric Rheumatology International Trials Organisation (PRINTO). Arch Dis Child 2011;96:596-601.
8. Ruperto N, Martini A. International research networks in pediatric rheumatology: the PRINTO perspective. Curr Opin Rheumatol 2004;16:566-70. (Pubitemid 39128326)
9. Ruperto N, Ravelli A, Murray KJ, et al. Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. Rheumatology (Oxford) 2003;42:1452-9. (Pubitemid 37508918)
10. Ruperto N, Ravelli A, Cuttica R, et al. The Pediatric Rheumatology International Trials Organization criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: Prospective validation of the disease activity core set. Arthritis Rheum 2005;52:2854-64. (Pubitemid 41369116)
11. Ruperto N, Ravelli A, Oliveira S, et al. The Pediatric Rheumatology International Trials Organization/American College of Rheumatology provisional criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus. Prospective validation of the definition of improvement. Arthritis Rheum 2006;55:355-63. (Pubitemid 43887020)
12. Ruperto N, Bazso A, Pistorio A, et al. Agreement between multi-dimensional and renal-specific response criteria in patients with juvenile systemic lupus erythematosus and renal disease. Clin Exp Rheumatol 2010;28:424-33.
13. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7. (Pubitemid 13221242)
14. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
15. Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35:630-40.
16. Vitali C, Bencivelli W, Isenberg DA, et al. Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. II. Identification of the variables indicative of disease activity and their use in the development of an activity score. Clin Exp Rheumatol 1992;10:541-7.
17. Vitali C, Bencivelli W, Mosca M, et al. Development of a clinical chart to compute different disease activity indices for systemic lupus erythematosus. J Rheumatol 1999;26:498-501. (Pubitemid 29066764)
18. Liang MH, Socher SA, Larson MG, et al. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989;32:1107-18. (Pubitemid 19237865)
19. Laposata M. SI unit conversion guide. The New England Journal of Medicine 1992;1-109;NEJM Books, Boston, MA.
20. Schwartz GJ, Haycock GB, Spitzer A. Plasma creatinine and urea concentration in children: normal values for age and sex. J Pediatr 1976;88:828-30.
21. Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003;139:137-47.
22. Renal Disease Subcommittee of the American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria. The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. Arthritis Rheum 2006;54:421-32.
23. Ruperto N, Ravelli A, Pistorio A, et al. The provisional Pediatric Rheumatology International Trial Organization/American College of Rheumatology/European League Against Rheumatism disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: a prospective validation study. Arthritis Rheum 2008;59:4-13. (Pubitemid 351171873)
24. Brunner HI, Higgins GC, Wiers K, et al. Prospective validation of the provisional criteria for the evaluation of response to therapy in childhood-onset systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2010;62:335-44.
25. Lau KK, Jones DP, Hastings MC, et al. Short-term outcomes of severe lupus nephritis in a cohort of predominantly African-American children. Pediatr Nephrol 2006;21:655-62.
26. Descloux E, Durieu I, Cochat P, et al. Influence of age at disease onset in the outcome of paediatric systemic lupus erythematosus. Rheumatology (Oxford) 2009;48:779-84.
27. Hersh AO, Trupin L, Yazdany J, et al. Childhood-onset disease as a predictor of mortality in an adult cohort of patients with systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2010;62:1152-9.
28. Sato V, Marques I, Goldenstein P, et al. Lupus nephritis is more severe in children and adolescents than in older adults. Lupus 2012;21:978-83.
29. Feldman BM, Rider LG, Reed AM, et al. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet 2008;371:2201-12. (Pubitemid 351890413)
30. Rouster-Stevens KA, Gursahaney A, Ngai KL, et al. Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with juvenile dermatomyositis. Arthritis Rheum 2008;59:222-6. (Pubitemid 351272958)
31. Brunner HI, Klein-Gitelman MS, Ying J, et al. Corticosteroid use in childhood-onset systemic lupus erythematosus-practice patterns at four pediatric rheumatology centers. Clin Exp Rheumatol 2009;27:155-62.
32. Reiff A, Rawlings DJ, Shaham B, et al. Preliminary evidence for cyclosporin A as an alternative in the treatment of recalcitrant juvenile rheumatoid arthritis and juvenile dermatomyositis. J Rheumatol 1997;24:2436-43. (Pubitemid 28005149)
33. Pistoia V, Buoncompagni A, Scribanis R, et al. Cyclosporin A in the treatment of juvenile chronic arthritis and childhood polymyositis- dermatomyositis. Results: of a preliminary study. Clin Exp Rheumatol 1993;11:203-8. (Pubitemid 23155993)
34. Heckmatt J, Hasson N, Saunders C, et al. Cyclosporin in juvenile dermatomyositis. Lancet 1989;1:1063-6. (Pubitemid 19123068)
35. Contreras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004;350:971-80. (Pubitemid 38269274)
36. Mina R, von SE, Ardoin SP, et al. Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2012;64:375-83.
37. Brunner HI, Huggins J, Klein-Gitelman MS. Pediatric SLE-towards a comprehensive management plan. Nat Rev Rheumatol 2011;7:225-33.
38. Bertsias G, Ioannidis JP, Boletis J, et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 2008;67:195-205. (Pubitemid 351183308)
39. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012;71:177-82.
40. Barbano G, Gusmano R, Damasio B, et al. Childhood-onset lupus nephritis: a single-center experience of pulse intravenous cyclophosphamide therapy. J Nephrol 2002;15:123-9. (Pubitemid 34594161)
41. Ravelli A, Ruperto N, Martini A. Outcome in juvenile onset systemic lupus erythematosus. Curr Opin Rheumatol 2005;17:568-73. (Pubitemid 41527817)
42. Robak E, Robak T. Monoclonal antibodies in the treatment of systemic lupus erythematosus. Curr Drug Targets 2009;10:26-37.